Abstract
Living donor renal transplantation affords numerous benefits to the recipient and donor alike. However, living donor renal transplantation continues to lag behind deceased donor transplants in the USA for a variety of reasons. These include a lack of awareness among patients, patients’ families, health-care professionals, and the public about its benefits, sociocultural factors leading to mistrust of the health-care system, a significant financial burden on potential donors, and lastly biomedical factors that hinder living donation such as ABO/HLA incompatibility among donor-recipient dyads. Understanding the nuances of these barriers is critical in order to address and overcome them. This chapter explores these impediments and the strategies that are being employed to combat them and thereby increase living organ donation. Strategies discussed include ways to educate stakeholders about the logistics and the benefits of living donor renal transplantation, removing financial disincentives for organ donors, developing systems to enable donor exchanges and altruistic donation, and biomedical strategies to overcome the ABO/HLA incompatibility barrier.
References
Ahmad N, Ahmed K, Khan MS, Calder F, Mamode N, Taylor J, Koffman G (2008) Living-unrelated donor renal transplantation: an alternative to living-related donor transplantation? Ann R Coll Surg Engl 90(3):247–250. doi:10.1308/003588408X261636
Aikawa A, Kawamura T, Shishido S, Saito K, Takahashi K, members AB-ITC (2014) ABO-incompatible living-donor pediatric kidney transplantation in Japan. Clinics (Sao Paulo) 69(Suppl 1):22–27
Alkhunaizi AM, de Mattos AM, Barry JM, Bennett WM, Norman DJ (1999) Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 67(10):1319–1324
Axelrod DA, McCullough KP, Brewer ED, Becker BN, Segev DL, Rao PS (2010) Kidney and pancreas transplantation in the United States, 1999–2008: the changing face of living donation. Am J Transplant 10(4 Pt 2):987–1002. doi:10.1111/j.1600-6143.2010.03022.x
Balhara KS, Kucirka LM, Jaar BG, Segev DL (2012) Disparities in provision of transplant education by profit status of the dialysis center. Am J Transplant 12(11):3104–3110. doi:10.1111/j.1600-6143.2012.04207.x
Ballow M (2014) Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 14(6):509–515. doi:10.1097/ACI.0000000000000116
Becker LE, Siebert D, Susal C, Opelz G, Leo A, Waldherr R, Macher-Goeppinger S, Schemmer P, Schaefer SM, Klein K, Beimler J, Zeier M, Schwenger V, Morath C (2015) Outcomes following ABO-incompatible kidney transplantation performed after desensitization by nonantigen-specific immunoadsorption. Transplantation 99(11):2364–2371. doi:10.1097/TP.0000000000000753
Bentall A, Cornell LD, Gloor JM, Park WD, Gandhi MJ, Winters JL, Chedid MF, Dean PG, Stegall MD (2013) Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 13(1):76–85. doi:10.1111/j.1600-6143.2012.04291.x
Bock GH, Conners CK, Ruley J, Samango-Sprouse CA, Conry JA, Weiss I, Eng G, Johnson EL, David CT (1989) Disturbances of brain maturation and neurodevelopment during chronic renal failure in infancy. J Pediatr 114(2):231–238
Boulware LE, Ratner LE, Sosa JA, Cooper LA, LaVeist TA, Powe NR (2002) Determinants of willingness to donate living related and cadaveric organs: identifying opportunities for intervention. Transplantation 73(10):1683–1691
Bryan CF, Nelson PW, Shield CF, Warady BA, Winklhofer FT, Murillo D, Wakefield MR (2007) Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. Am J Transplant 7(5):1181–1184. doi:10.1111/j.1600-6143.2007.01750.x
Brynger H, Rydberg L, Samuelsson B, Blohme I, Lindholm A, Sandberg L (1983) Renal transplantation across a blood group barrier – ‘A2’ kidneys to ‘O’ recipients. Proc Eur Dial Transplant Assoc 19:427–431
Butani L, Perez RV (2011) Effect of pretransplant dialysis modality and duration on long-term outcomes of children receiving renal transplants. Transplantation 91(4):447–451. doi:10.1097/TP.0b013e318204860b
Buyan N, Turkmen MA, Bilge I, Baskin E, Haberal M, Bilginer Y, Mir S, Emre S, Akman S, Ozkaya O, Fidan K, Alpay H, Kavukcu S, Sever L, Ozcakar ZB, Dogrucan N (2010) Quality of life in children with chronic kidney disease (with child and parent assessments). Pediatr Nephrol 25(8):1487–1496. doi:10.1007/s00467-010-1486-1
Cereb N, Kim HR, Ryu J, Yang SY (2015) Advances in DNA sequencing technologies for high resolution HLA typing. Hum Immunol 76(12):923–927. doi:10.1016/j.humimm.2015.09.015
Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M (2015) Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics 135(2):e551–e555. doi:10.1542/peds.2014-2275
Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD (2015) Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 15(5):1293–1302. doi:10.1111/ajt.13168
Cravedi P, Heeger PS (2014) Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest 124(6):2348–2354. doi:10.1172/JCI72273
de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Weimar W, Claas FH (2008) A flexible national living donor kidney exchange program taking advantage of a central histocompatibility laboratory: the Dutch model. Clin Transpl 8:69–73
Dorje C, Mjoen G, Strom EH, Holdaas H, Jenssen T, Oyen O, Akkok CA, Cvancarova M, Midtvedt K, Reisaeter AV (2015) One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts. Clin Transplant 29(3):268–276. doi:10.1111/ctr.12515
Duquesnoy RJ (2014) HLA epitope based matching for transplantation. Transpl Immunol 31(1):1–6. doi:10.1016/j.trim.2014.04.004
Duquesnoy RJ, Gebel HM, Woodle ES, Nickerson P, Baxter-Lowe LA, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gerlach JA, Fung JJ, Kamoun M, Middleton D, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A (2015a) High-resolution HLA typing for sensitized patients: advances in medicine and science require us to challenge existing paradigms. Am J Transplant 15(10):2780–2781. doi:10.1111/ajt.13376
Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, Woodle ES, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gebel HM, Gerlach JA, Fung JJ, Middleton D, Nickerson P, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A (2015b) Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant 15(4):923–930. doi:10.1111/ajt.13167
Flechner SM, Leeser D, Pelletier R, Morgievich M, Miller K, Thompson L, McGuire S, Sinacore J, Hil G (2015) The incorporation of an advanced donation program into kidney paired exchange: initial experience of the National Kidney Registry. Am J Transplant 15(10):2712–2717. doi:10.1111/ajt.13339
Gillespie A, Hammer H, Bass SB, Ouzienko V, Obradovic Z, Urbanski M, Browne T, Silva P (2015) Attitudes towards living donor kidney transplantation among urban African American hemodialysis patients: a qualitative and quantitative analysis. J Health Care Poor Underserved 26(3):852–872. doi:10.1353/hpu.2015.0087
Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, Stegall MD (2006) Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6(8):1841–1847. doi:10.1111/j.1600-6143.2006.01416.x
Gore JL, Danovitch GM, Litwin MS, Pham PT, Singer JS (2009) Disparities in the utilization of live donor renal transplantation. Am J Transplant 9(5):1124–1133. doi:10.1111/j.1600-6143.2009.02620.x
Gore JL, Singer JS, Brown AF, Danovitch GM (2012) The socioeconomic status of donors and recipients of living unrelated renal transplants in the United States. J Urol 187(5):1760–1765. doi:10.1016/j.juro.2011.12.112
Hidalgo G, Tejani C, Clayton R, Clements P, Distant D, Vyas S, Baqi N, Singh A (2001) Factors limiting the rate of living-related kidney donation to children in an inner city setting. Pediatr Transplant 5(6):419–424
Higgins R, Lowe D, Hathaway M, Williams C, Lam FT, Kashi H, Tan LC, Imray C, Fletcher S, Chen K, Krishnan N, Hamer R, Daga S, Edey M, Zehnder D, Briggs D (2011) Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 92(8):900–906. doi:10.1097/TP.0b013e31822dc38d
Higgins RM, Daga S, Mitchell DA (2015) Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant 30(12):1972–1978. doi:10.1093/ndt/gfu375
Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, Russell PS, Colvin RB (2012) A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 12(2):313–321. doi:10.1111/j.1600-6143.2011.03836.x
Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Terasaki PI (2008) Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl 6:229–239
Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA (2015) A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int 87(2):409–416. doi:10.1038/ki.2014.261
Jordan SC, Vo AA (2013) Evolving concepts in desensitization. Clin Transpl 19:285–292
Jordan SC, Vo AA (2014) Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches. Curr Opin Organ Transplant 19(6):591–597. doi:10.1097/MOT.0000000000000128
Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J (2004) Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15(12):3256–3262. doi:10.1097/01.ASN.0000145878.92906.9F
Jordan SC, Choi J, Vo A (2015) Kidney transplantation in highly sensitized patients. Br Med Bull 114(1):113–125. doi:10.1093/bmb/ldv013
Kurella Tamura M, Li S, Chen SC, Cavanaugh KL, Whaley-Connell AT, McCullough PA, Mehrotra RL (2014) Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. Kidney Int 85(3):686–692. doi:10.1038/ki.2013.369
Lo P, Sharma A, Craig JC, Wyburn K, Lim W, Chapman JR, Palmer SC, Strippoli GF, Wong G (2015) Preconditioning therapy in ABO-incompatible living kidney transplantation: a systematic review and meta-analysis. Transplantation. doi:10.1097/TP.0000000000000933
Loupy A, Hill GS, Jordan SC (2012) The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 8(6):348–357. doi:10.1038/nrneph.2012.81
Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Fremeaux-Bacchi V, Mejean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X (2013) Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 369(13):1215–1226. doi:10.1056/NEJMoa1302506
Martin DE, White SL (2015) Financial incentives for living kidney donors: are they necessary? Am J Kidney Dis 66(3):389–395. doi:10.1053/j.ajkd.2015.03.041
May LJ, Yeh J, Maeda K, Tyan DB, Chen S, Kaufman BD, Bernstein D, Rosenthal DN, Hollander SA (2014) HLA desensitization with bortezomib in a highly sensitized pediatric patient. Pediatr Transplant 18(8):E280–E282. doi:10.1111/petr.12347
Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL (2011) Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365(4):318–326. doi:10.1056/NEJMoa1012376
Nelson PW, Helling TS, Shield CF, Beck M, Bryan CF (1992) Current experience with renal transplantation across the ABO barrier. Am J Surg 164(5):541–544, discussion 544–545
Nelson PW, Hughes TM, Beck ML, Warady BA, Aeder MI, Helling TS, Landreneau MD, Luger AM, Pierce GE, Ross G et al (1996) Stratification and successful transplantation of patients awaiting ABO-incompatible (A2 into B and O) transplantation by A-isoagglutinin-titer phenogroup. Transplant Proc 28(1):221–223
Nguyen S, Gallay B, Butani L (2014) Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen. Pediatr Transplant 18(5):463–468. doi:10.1111/petr.12274
Okumi M, Toki D, Nozaki T, Shimizu T, Shirakawa H, Omoto K, Inui M, Ishida H, Tanabe K (2015) ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am J Transplant. doi:10.1111/ajt.13502
Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA (2014) Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 98(8):857–863. doi:10.1097/TP.0000000000000298
Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141(2):191–197. doi:10.1067/mpd.2002.125910
Park WD, Grande JP, Ninova D, Nath KA, Platt JL, Gloor JM, Stegall MD (2003) Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 3(8):952–960
Rees MA, Kopke JE, Pelletier RP, Segev DL, Rutter ME, Fabrega AJ, Rogers J, Pankewycz OG, Hiller J, Roth AE, Sandholm T, Unver MU, Montgomery RA (2009) A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 360(11):1096–1101. doi:10.1056/NEJMoa0803645
Revollo JY, Cuffy MC, Abu Jawdeh BG, Paterno F, Girnita A, Brailey P, Alloway RR, Woodle ES (2015) Case report: successful living donor kidney transplantation in a highly human leukocyte antigen-sensitized recipient with a positive cytotoxic crossmatch using bortezomib-based desensitization without intravenous immunoglobulin. Transplant Proc 47(7):2254–2257. doi:10.1016/j.transproceed.2015.05.028
Rodrigue JR, Schold JD, Mandelbrot DA (2013) The decline in living kidney donation in the United States: random variation or cause for concern? Transplantation 96(9):767–773. doi:10.1097/TP.0b013e318298fa61
Rodrigue JR, Kazley AS, Mandelbrot DA, Hays R, LaPointe Rudow D, Baliga P (2015) Living donor kidney transplantation: overcoming disparities in live kidney donation in the US-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1687–1695. doi:10.2215/CJN.00700115
Salter ML, Orandi B, McAdams-DeMarco MA, Law A, Meoni LA, Jaar BG, Sozio SM, Kao WH, Parekh RS, Segev DL (2014) Patient- and provider-reported information about transplantation and subsequent waitlisting. J Am Soc Nephrol 25(12):2871–2877. doi:10.1681/ASN.2013121298
Smith JM, Martz K, Blydt-Hansen TD (2013) Pediatric kidney transplant practice patterns and outcome benchmarks, 1987–2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant 17(2):149–157. doi:10.1111/petr.12034
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11(11):2405–2413. doi:10.1111/j.1600-6143.2011.03757.x
Tan JC, Gordon EJ, Dew MA, LaPointe Rudow D, Steiner RW, Woodle ES, Hays R, Rodrigue JR, Segev DL (2015) Living donor kidney transplantation: facilitating education about live kidney donation-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1670–1677. doi:10.2215/CJN.01030115
Tierney J, Shaffer D (2015) Transplantation of ABO A2 kidneys into O recipients: do IgM anti-A1 titers matter? Clin Transplant 29(4):379–382. doi:10.1111/ctr.12527
Tong A, Chapman JR, Wong G, Craig JC (2014) Perspectives of transplant physicians and surgeons on reimbursement, compensation, and incentives for living kidney donors. Am J Kidney Dis 64(4):622–632. doi:10.1053/j.ajkd.2014.02.019
Tushla L, Rudow DL, Milton J, Rodrigue JR, Schold JD, Hays R (2015) Living-donor kidney transplantation: reducing financial barriers to live kidney donation-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1696–1702. doi:10.2215/CJN.01000115
Tyden G, Kumlien G, Berg UB (2011) ABO-incompatible kidney transplantation in children. Pediatr Transplant 15(5):502–504. doi:10.1111/j.1399-3046.2011.01480.x
Valentini RP, Nehlsen-Cannarella SL, Gruber SA, Mattoo TK, West MS, Lang C, Imam AA (2007) Intravenous immunoglobulin, HLA allele typing and HLA matchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Pediatr Transplant 11(1):77–81. doi:10.1111/j.1399-3046.2006.00617.x
Valli PV, Puga Yung G, Fehr T, Schulz-Huotari C, Kaup N, Gungor T, Ambuhl P, Weber M, Schanz U, Seebach JD, Stussi G (2009) Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant 9(5):1072–1080. doi:10.1111/j.1600-6143.2009.02579.x
Van Arendonk KJ, Orandi BJ, James NT, Segev DL, Colombani PM (2013) Living unrelated renal transplantation: a good match for the pediatric candidate? J Pediatr Surg 48(6):1277–1282. doi:10.1016/j.jpedsurg.2013.03.023
Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359(3):242–251. doi:10.1056/NEJMoa0707894
Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC (2010) Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89(9):1095–1102. doi:10.1097/TP.0b013e3181d21e7f
Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R, Mackowiak J, Jordan SC (2013) Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 95(6):852–858. doi:10.1097/TP.0b013e3182802f88
Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC (2014) Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 98(3):312–319. doi:10.1097/TP.0000000000000064
Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, Toyoda M, Ge S, Haas M, Puliyanda D, Reinsmoen N, Peng A, Villicana R, Jordan SC (2015a) A phase I/II trial of the interleukin-6 receptor specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. doi:10.1097/TP.0000000000000741
Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC (2015b) Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation 99(7):1423–1430. doi:10.1097/TP.0000000000000525
Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, Peng A, Villicana R, Puliyanda D, Reinsmoen N, Haas M, Jordan SC (2015c) A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99(2):299–308. doi:10.1097/TP.0000000000000592
Wahrmann M, Haidinger M, Kormoczi GF, Weichhart T, Saemann MD, Geyeregger R, Kikic Z, Prikoszovich T, Drach J, Bohmig GA (2010) Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 89(11):1385–1390. doi:10.1097/TP.0b013e3181d9e1c0
Warren PH, Gifford KA, Hong BA, Merion RM, Ojo AO (2014) Development of the National Living Donor Assistance Center: reducing financial disincentives to living organ donation. Prog Transplant 24(1):76–81. doi:10.7182/pit2014593
Waterman AD, Morgievich M, Cohen DJ, Butt Z, Chakkera HA, Lindower C, Hays RE, Hiller JM, Lentine KL, Matas AJ, Poggio ED, Rees MA, Rodrigue JR, LaPointe Rudow D (2015) Living donor kidney transplantation: improving education outside of transplant centers about live donor transplantation-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1659–1669. doi:10.2215/CJN.00950115
Woodle ES, Shields AR, Ejaz NS, Sadaka B, Girnita A, Walsh RC, Alloway RR, Brailey P, Cardi MA, Abu Jawdeh BG, Roy-Chaudhury P, Govil A, Mogilishetty G (2015) Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant 15(1):101–118. doi:10.1111/ajt.13050
Zenios SA, Woodle ES, Ross LF (2001) Primum non nocere: avoiding harm to vulnerable wait list candidates in an indirect kidney exchange. Transplantation 72(4):648–654
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this entry
Cite this entry
Butani, L. (2016). Increasing Kidney Transplant Availability: Live Donation, Paired Donation, and Transplant Across ABO and HLA Barriers. In: Dunn, S., Horslen, S. (eds) Solid Organ Transplantation in Infants and Children. Organ and Tissue Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-08049-9_31-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-08049-9_31-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Online ISBN: 978-3-319-08049-9
eBook Packages: Springer Reference MedicineReference Module Medicine